Parallel Advisors LLC Acquires 3,742 Shares of Novartis AG $NVS

Parallel Advisors LLC grew its holdings in shares of Novartis AG (NYSE:NVS) by 29.6% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 16,366 shares of the company’s stock after acquiring an additional 3,742 shares during the quarter. Parallel Advisors LLC’s holdings in Novartis were worth $2,500,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently made changes to their positions in the stock. J.W. Cole Advisors Inc. increased its position in Novartis by 0.6% during the 4th quarter. J.W. Cole Advisors Inc. now owns 10,577 shares of the company’s stock worth $1,348,000 after purchasing an additional 64 shares in the last quarter. Roundview Capital LLC boosted its position in Novartis by 2.5% in the fourth quarter. Roundview Capital LLC now owns 2,711 shares of the company’s stock valued at $374,000 after buying an additional 66 shares in the last quarter. IMA Advisory Services Inc. grew its stake in shares of Novartis by 10.9% during the fourth quarter. IMA Advisory Services Inc. now owns 710 shares of the company’s stock worth $98,000 after buying an additional 70 shares during the last quarter. Abundance Wealth Counselors grew its stake in shares of Novartis by 0.4% during the fourth quarter. Abundance Wealth Counselors now owns 16,927 shares of the company’s stock worth $2,334,000 after buying an additional 73 shares during the last quarter. Finally, Atlantic Edge Private Wealth Management LLC increased its holdings in shares of Novartis by 3.5% during the fourth quarter. Atlantic Edge Private Wealth Management LLC now owns 2,230 shares of the company’s stock worth $307,000 after buying an additional 75 shares in the last quarter. Institutional investors own 13.12% of the company’s stock.

Key Novartis News

Here are the key news stories impacting Novartis this week:

• Positive Sentiment: Novartis topped Q2 earnings estimates, posting $2.41 per share versus $2.17 expected, while revenue also came in above forecasts. The beat was driven by strong demand for key drugs and lower-than-expected costs. Novartis earnings report
• Positive Sentiment: The company returned to sales growth in Q2 as newer medicines offset generic pressure, with strength in cancer and multiple sclerosis treatments helping support results. Reuters Q2 profit story
• Positive Sentiment: Management reaffirmed full-year 2026 guidance, which suggests confidence that growth from newer products can continue despite headwinds. Zacks earnings recap
• Neutral Sentiment: Investors are also watching upcoming late-stage trial readouts in the second half of the year, which could influence the stock’s longer-term valuation narrative. Reuters pipeline valuation story
• Negative Sentiment: Ongoing generic competition and a sharp drop in Entresto sales remain major headwinds, and investors may worry about pressure on older blockbusters. Invezz Entresto sales drop story

Analyst Ratings Changes

Several research firms recently weighed in on NVS. Morgan Stanley raised their price objective on Novartis from $143.00 to $170.00 and gave the company an “overweight” rating in a report on Thursday, March 26th. Weiss Ratings cut Novartis from a “buy (a-)” rating to a “buy (b)” rating in a report on Wednesday, April 29th. Seven investment analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $141.20.

Novartis Trading Up 2.8%

Shares of NYSE NVS opened at $153.82 on Wednesday. The firm has a 50 day moving average price of $151.61 and a two-hundred day moving average price of $151.88. The stock has a market cap of $293.51 billion, a P/E ratio of 22.04, a price-to-earnings-growth ratio of 2.58 and a beta of 0.45. Novartis AG has a 52-week low of $112.34 and a 52-week high of $170.46. The company has a debt-to-equity ratio of 0.96, a quick ratio of 0.65 and a current ratio of 0.85.

Novartis (NYSE:NVS) last issued its quarterly earnings results on Tuesday, June 30th. The company reported $2.41 EPS for the quarter. Novartis had a net margin of 24.87% and a return on equity of 38.82%. The company had revenue of $14.95 billion for the quarter. As a group, equities analysts forecast that Novartis AG will post 8.75 EPS for the current year.

Novartis Company Profile

Novartis is a Swiss multinational pharmaceutical company headquartered in Basel that researches, develops, manufactures and commercializes prescription medicines and related health-care products. Formed through the 1996 merger of Ciba-Geigy and Sandoz, Novartis operates globally and focuses on bringing therapeutics from discovery through clinical development to commercial markets worldwide.

The company’s activities center on innovative pharmaceuticals across several therapeutic areas, including oncology, immunology, cardiovascular and metabolic diseases, neuroscience and ophthalmology, alongside capabilities in advanced therapies such as biologics, cell and gene therapies.